Celldex Therapeutics (NASDAQ:CLDX) was formed in 2008 as the result of a merger between AVANT Immunotherapeutics - which was formed following the merger of T Cell Sciences Inc and Virus Research Institute Inc in 1998 - and long time SBIR involved firm, and NJ based Celldex in 2008. Celldex Therapeutics, Inc., a biopharmaceutical company with an emphasis on developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The firm's pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Currently, the firm's pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies having the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.
